** Shares of Vanda Pharmaceuticals rise 21.2% to $5.35 premarket
** UK-based Cycle Pharmaceuticals reaffirms all-cash proposal to acquire Vanda for $8.00 per share which would value it at $488 million
** Cycle says the proposal represents a 80% premium to Vanda's share price as on Oct. 11 compared to a 58% premium to its price on June 5, 2024, the day prior to the public disclosure of Cycle's initial offer
** Cycle had made the offer on June 6 for $8/shr which was rejected by Vanda
** The company also sent a proposal in September reiterating the offer, which was also rejected by Vanda on Oct. 7
** Up to last close, stock up 5.2% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。